Martin Dreyling

Martin Dreyling is a leading German lymphoma expert who contributed to pivotal ZUMA-5 trial establishing axicabtagene ciloleucel (axi-cel) CAR-T therapy for relapsed/refractory follicular lymphoma. His research spans the biology and treatment of indolent B-cell lymphomas with emphasis on translating novel immunotherapies including CAR-T cells into clinical practice. He leads European lymphoma studies through EMCL and EBMT networks. His work has helped define optimal patient selection for CAR-T in FL and approaches to manage CAR-T toxicity in this context.